Meeting
2013 ASCO Annual Meeting
Phase I/II trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) followed by concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Authors
Hironaga Satake
National Cancer Center Hospital East, Kashiwa, Japan
Hironaga Satake , Makoto Tahara , Satoshi Mochizuki , Sadamoto Zenda , Takashi Kojima , Hideaki Bando , Tomoko Yamazaki , Ken Kato , Satoru Iwasa , Yoshitaka Honma , Hiroki Hara , Tomoya Yokota , Satoshi Hamauchi , Naomi Kiyota , Takayuki Kii , Keisho Chin , Atsushi Ohtsu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
UMIN000003370
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4074)
DOI
10.1200/jco.2013.31.15_suppl.4074
Abstract #
4074
Poster Bd #
20D
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
A phase I/II study of divided-dose docetaxel, cisplatin, and fluorouracil (DCF) for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
First Author: Toshiyasu Ojima
Poster
2013 ASCO Annual Meeting
Induction chemotherapy (CT) with docetaxel, cisplatin, and fluorouracil (TPF) followed by concomitant cisplatin plus radiotherapy in locally advanced nasopharyngeal cancer (NPC): Results after 06 years.
First Author: Esma Kerboua
Poster
2014 ASCO Annual Meeting
Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma.
First Author: Erminia Massarelli
Poster
2013 ASCO Annual Meeting
A comparative study of the response and toxicities in locally advanced head and neck cancer patients treated with paclitaxel, cisplatinum, 5-FU versus docetaxel, cisplatinum, 5-FU as neoadjuvant chemotherapy followed by concurrent chemoradiation.
First Author: Diptirani Samanta